

RNS number: 2093F
Company name: Research Pharmaceutical SRV, Inc
Category: Transaction in Own Shares
Headline: Transaction in Own Shares
Embargo: No
Related companies: None
Additional Distribution: None
Additional file: No
Webcast: No

ReSearch Pharmaceutical Services Inc.

Repurchase of Common Stock

ReSearch Pharmaceutical Services, Inc. (the "Company"), a leading provider of clinical development outsourcing solutions to the biopharmaceutical industry, announces that it has repurchased 750,000 shares of its common stock, at \$4.85 per share, from Pangaea One Acquisition Holdings I, LLC ("Pangaea") on October 4, 2007 ("Repurchase").

By virtue of Pangaea's shareholding in the Company prior to the Repurchase, (being 10,840,480 shares of common stock representing approximately 32.6 per cent of the Company's issued share capital) Pangaea is deemed to be a related party for the purposes of the AIM Rules.

Following (i) the full implementation of the terms of the share repurchases to be effected as part of the reverse takeover process by Cross Shore Acquisition Corporation, and (ii) the stock buyback from Pangaea, 32,535,223 common shares will be in issue. Following the Repurchase, Pangaea's shareholding will reduce from 32.9 per cent to 31.3 per cent of the outstanding issued share capital accordingly. In addition, Pangaea will hold 100,000 common stock warrants.

The entire consideration for the Repurchase, being US\$3,637,500 in aggregate, is being funded out of the Company's operating funds and is not expected to have a material impact on the Company's business or operations, financial or otherwise.

The directors of the Company, having consulted the Company's nominated adviser Arbuthnot Securities Limited, consider that the terms of the repurchase are fair and reasonable insofar as the Company's stockholders are concerned.

Pangaea is an affiliate of Cartesian Capital Group, LLC ("Cartesian"), a private equity firm based in New York, that manages alternative investments worldwide, with a special focus on the world's emerging markets.

For further information please contact:

ReSearch Pharmaceutical Services, Inc. +1-215-540-0700
Daniel M. Perlman, Chairman & Chief Executive Officer
Steven Bell, Chief Financial Officer

Nominated Adviser and UK Broker: +44-20-7012-2100
Arbuthnot Securities Limited
James Steel/Guy Blakeney